This information is intended for Healthcare Professionals in the UK.
By proceeding you are confirming that you are a Healthcare Professional.
Welcome to the Himalayas - the highest region on Earth
This is an interactive 360° experience
Move your device around to explore the mountain scenery
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Astellas Pharma Ltd. on 0800 783 5018.
EVRENZOTM▼ (roxadustat) is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).1
Prescribing information is available on request, via our portal or from your local Astellas representative.
1. EVRENZO (roxadustat) Summary of Product Characteristics.
MAT-UK-EVZ-2023-00162. Date of preparation: May 2023.
